Back to results
US 2012/0252022 A1Published application
Methods and compositions for the diagnosis and treatment of thyroid cancer
OwnerPaul Walfish, Ranju Ralhaninventors
Life of this patent
Estimating the term…
Abstract
Methods for detecting, diagnosing and monitoring thyroid cancer in a subject are described comprising measuring in a sample from the subject markers including Ep-ICD and β-catenin. The invention also provides kits and compositions for carrying out the methods of the invention.
Claims25
(canceled)
A method for diagnosing thyroid cancer in a subject comprising:
- (a) detecting or identifying in a sample from the patient, levels of one or more thyroid cancer markers comprising Ep-ICD and, optionally EpEx;
- (b) comparing the detected levels of the thyroid cancer markers with control levels, wherein a significant difference in the level of at least one of the thyroid cancer markers relative to the corresponding control level is indicative of thyroid cancer.
-7. (canceled)
A method for diagnosing the aggressiveness or metastatic potential of a thyroid cancer in a subject comprising:
- (a) contacting a sample from the subject with an agent capable of detecting a thyroid cancer marker;
- (b) detecting in the sample the thyroid cancer marker;
- and
- (c) comparing the detected amount with an amount detected for a standard, wherein the thyroid cancer marker is Ep-ICD and optionally EpEx, wherein a higher level of Ep-ICD, optionally together with a lower level of EpEx correlates with a more aggressive or increased metastatic potential of thyroid cancer, while a lower level of Ep-ICD and optionally together with a higher level of EpEx correlates with a less aggressive or lower metastatic potential of thyroid cancer.
1 more element
A method for monitoring the progression of a thyroid cancer in a subject, the method comprising:
- (a) detecting in a sample from a patient at a first time point, a thyroid cancer marker;
- (b) repeating step (a) at a subsequent point in time;
- and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of the cancer, wherein the thyroid cancer marker is Ep-ICD and optionally EpEx.
(canceled)
-25. (canceled)
-31. (canceled)
Dependencies are inferred from the claim text.